M
Michelle Parish
Researcher at Johns Hopkins University
Publications - 3
Citations - 162
Michelle Parish is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Lopinavir & Amprenavir. The author has an hindex of 3, co-authored 3 publications receiving 108 citations. Previous affiliations of Michelle Parish include University of Virginia.
Papers
More filters
Journal ArticleDOI
Cognitive Decline after Delirium in Patients Undergoing Cardiac Surgery.
Charles H. Brown,Julia Probert,Ryan Healy,Michelle Parish,Yohei Nomura,Atsushi Yamaguchi,Jing Tian,Kenton J. Zehr,Kaushik Mandal,Vidyulata Kamath,Karin J. Neufeld,Charles W. Hogue +11 more
TL;DR: Patients who developed delirium had greater decline in a composite measure of cognition and in visuoconstruction and processing speed domains at 1 month and 1 yr after cardiac surgery, and the differences in cognitive change byDelirium were not significant at 1 yr, with the exception of processing speed.
Journal ArticleDOI
A Multicenter Pilot Study Assessing Regional Cerebral Oxygen Desaturation Frequency During Cardiopulmonary Bypass and Responsiveness to an Intervention Algorithm
Balachundhar Subramanian,Charles B. Nyman,Maria D. Fritock,Rebecca Y. Klinger,Roman M. Sniecinski,Philip E. Roman,Julie L. Huffmyer,Michelle Parish,Gayane Yenokyan,Charles W. Hogue +9 more
TL;DR: This multicenter pilot study found that 50% to 75% of patients undergoing cardiac surgery experience one or more rScO2 desaturations during CPB, suggesting that appropriate alarming systems should be adopted to alert clinicians of such events.
Journal ArticleDOI
Amprenavir and Lopinavir Pharmacokinetics following Coadministration of Amprenavir or Fosamprenavir with Lopinavir/Ritonavir, with or without Efavirenz:
Paul A. Pham,Craig W. Hendrix,Patricia Barditch-Crovo,Teresa L. Parsons,Wasif A. Khan,Michelle Parish,Christine Radebaugh,Kathryn A. Carson,Gary E Pakes,Roula B Qaqish,Charles Flexner +10 more
TL;DR: EFV did not appear to significantly alter APV and LPV pharmacokinetic parameters in HIV-infected patients taking APV 750mg twice daily + LPV 533/133 mg twice daily and switching FPV to FPV resulted in an increase in APV Cmin, AUC, and Cmax without changing LPV or RTV pharmacokinetics or overall tolerability.